Stefan Menzl, Director of International Regulatory Affairs at Abbott Medical Optics, discusses post-market clinical surveillance and follow-up. He outlines the requirements for post-market surveillance under the current Medical Device Directive and proposed new Medical Device Regulation. Key elements of a post-market surveillance plan include vigilance reporting, literature review, registries, and clinical studies. Challenges to meeting requirements include non-harmonized regulations worldwide and ensuring safety data is consistently updated from various sources.
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCERamakrishna K
An introduction to pharmacovigilance, basic types like active pharmacovigilance and passive pharmacovigilance, purpose, adverse event reporting, data processing, causality, assessement, signal detection, risk management plans and analysis
Pharmacovigilance - a regulator's perspectiveTGA Australia
This presentation provides an overview of the TGA's Pre-market and Post-market pharmacovigilance methods. It describes the role and content of Risk Management Plans as well as adverse event reporting and signal detection and investigation.
Post-Market Clinical Follow Up Studies Under EU MDR and IVDREMMAIntl
On May 5, 2017, the Active Implantable Medical Devices Directive (90/385/EEC — AIMD) and the Medical Devices Directive (93/42/EEC — MDD) were replaced by the Medical Device Regulations (MDR) 2017/745, and the In-Vitro Diagnostic Medical Devices Directive (89/79/EC — IVDD) was replaced by the In-Vitro Diagnostic Regulations (IVDR) 2017/746.
Both of these new regulations put a heavy emphasis on post-market surveillance activities for a product. Post-market clinical follow-up studies, or performance studies as called in the IVDR, are an integral part of the post-market surveillance requirements of the newly released regulations. PMCF studies must be initiated by the manufacturer...
Understanding Post-market Surveillance under EU MDR: Being Proactive, not Rea...Greenlight Guru
While the enforcement of EU MDR might have been delayed another year, your preparations addressing requirements for post-market surveillance (PMS) should not be! These new PMS requirements push manufacturers to take a more active role in monitoring of their devices to ensure that the benefit-risk profile of the device remains current. Performing PMS activities, according to the risk class of the device, requires a cross-functional team to ensure the required sources of data can be accessed and accurate data gathered. In this session, learn why it is important that PMS is not a one-size fits all approach, with considerations for risk of device, lifetime of device, time of the market, and more.
Talk takeaways:
• Understanding the new requirements of PMS under MDR
• What is the impact to the business?
• How do the requirements affect your current product lifecycle approach/QMS?
• Relationship between PMCF and PMS
• What to include in your plans and reports?
This session took place live at the Greenlight Guru True Quality Virtual Summit, a three-day event for medical device professionals to learn to get their devices to market faster, stay ahead of regulatory changes, and use quality as their multiplier to grow their device business.
Literature Surveillance in Pharmacovigilance; Current Trends, Methods and Challenges
Please join Elizabeth E. Garrard, PharmD, founder and CEO of Garrard Safety Solutions, as she reviews key issues in literature surveillance for Pharmacovigilance.
Objectives:
• Understand the regulatory obligations, best sources and procedures for conducting literature surveillance.
• Appreciate some examples of when a safety signal was detected in the literature and its impact on the lifecycle of a drug.
• Understand when to start and where to look for emerging safety information.
• Setting up your search strategy, how to ensure your search strings are well balanced, recognizing the challenges between precision and sensitivity.
• What is the impact of the new literature monitoring by EMA of a number of substances in selected medical literature to identify suspected adverse reactions with medicines authorized in the European Union. Early insights into successes and issues.
• Discuss current methods that can increase the likelihood of early detection of a safety issue and minimize the issues surrounding.
• Realize the challenges we face including wide differences in quality, accuracy, and completeness in the scientific literature and how best to navigate these differences and maintain proper vigilance.
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCERamakrishna K
An introduction to pharmacovigilance, basic types like active pharmacovigilance and passive pharmacovigilance, purpose, adverse event reporting, data processing, causality, assessement, signal detection, risk management plans and analysis
Pharmacovigilance - a regulator's perspectiveTGA Australia
This presentation provides an overview of the TGA's Pre-market and Post-market pharmacovigilance methods. It describes the role and content of Risk Management Plans as well as adverse event reporting and signal detection and investigation.
Post-Market Clinical Follow Up Studies Under EU MDR and IVDREMMAIntl
On May 5, 2017, the Active Implantable Medical Devices Directive (90/385/EEC — AIMD) and the Medical Devices Directive (93/42/EEC — MDD) were replaced by the Medical Device Regulations (MDR) 2017/745, and the In-Vitro Diagnostic Medical Devices Directive (89/79/EC — IVDD) was replaced by the In-Vitro Diagnostic Regulations (IVDR) 2017/746.
Both of these new regulations put a heavy emphasis on post-market surveillance activities for a product. Post-market clinical follow-up studies, or performance studies as called in the IVDR, are an integral part of the post-market surveillance requirements of the newly released regulations. PMCF studies must be initiated by the manufacturer...
Understanding Post-market Surveillance under EU MDR: Being Proactive, not Rea...Greenlight Guru
While the enforcement of EU MDR might have been delayed another year, your preparations addressing requirements for post-market surveillance (PMS) should not be! These new PMS requirements push manufacturers to take a more active role in monitoring of their devices to ensure that the benefit-risk profile of the device remains current. Performing PMS activities, according to the risk class of the device, requires a cross-functional team to ensure the required sources of data can be accessed and accurate data gathered. In this session, learn why it is important that PMS is not a one-size fits all approach, with considerations for risk of device, lifetime of device, time of the market, and more.
Talk takeaways:
• Understanding the new requirements of PMS under MDR
• What is the impact to the business?
• How do the requirements affect your current product lifecycle approach/QMS?
• Relationship between PMCF and PMS
• What to include in your plans and reports?
This session took place live at the Greenlight Guru True Quality Virtual Summit, a three-day event for medical device professionals to learn to get their devices to market faster, stay ahead of regulatory changes, and use quality as their multiplier to grow their device business.
Literature Surveillance in Pharmacovigilance; Current Trends, Methods and Challenges
Please join Elizabeth E. Garrard, PharmD, founder and CEO of Garrard Safety Solutions, as she reviews key issues in literature surveillance for Pharmacovigilance.
Objectives:
• Understand the regulatory obligations, best sources and procedures for conducting literature surveillance.
• Appreciate some examples of when a safety signal was detected in the literature and its impact on the lifecycle of a drug.
• Understand when to start and where to look for emerging safety information.
• Setting up your search strategy, how to ensure your search strings are well balanced, recognizing the challenges between precision and sensitivity.
• What is the impact of the new literature monitoring by EMA of a number of substances in selected medical literature to identify suspected adverse reactions with medicines authorized in the European Union. Early insights into successes and issues.
• Discuss current methods that can increase the likelihood of early detection of a safety issue and minimize the issues surrounding.
• Realize the challenges we face including wide differences in quality, accuracy, and completeness in the scientific literature and how best to navigate these differences and maintain proper vigilance.
Development safety update report (dsur) pharmacovigilance and safetyAzierta
According to ICH guideline E2F (Step 5) on Development Safety Update Reports (DSURs) already implemented since 2011, companies must submit DSURs on a yearly basis for medicinal products involved in clinical trials. The focus of the DSUR is on data and findings from clinical trials of drugs and biologicals, whether they are authorized or not.
DSURs are internationally-harmonized, safety documents covering the safety summary of medicinal products during their development or clinical trial phase.
They are based heavily on the PSUR format already used for updating the safety record of drugs in their marketing phase.
A DSUR should be prepared after the first authorization of a clinical trial worldwide. A copy of the DSUR should be submitted to each concerned European Member State (MS) if a clinical trial is authorized in this MS for this investigational drug (still using the DIBD). Therefore, the first DSUR can be submitted to a concerned MS earlier than 1 year, but the covered reporting period should not be longer than 1 year.
The DSUR presents an annual review & evaluation of safety information:
• Information reported during the current review period and analysis based on previous knowledge of the products’ safety
• Description of new issues that may impact the overall program or specific clinical trials.
• Summarization of current understanding and management of known and potential safety risks to exposed patients.
• Provide an update on the status of the clinical development program.
In Azierta, scientific and healthcare consulting, we are experts in Pharmacovigilance and we have a team of highly qualified drug safety experts who support our clients to manage pharmacovigilance in an optimal way. Our work covers all areas of pharmacovigilance, both at the level of medicines, as well as medical devices and cosmetic products.
If you are interested in the contents of the good practices of pharmacovigilance (GVPs), as well as in other products related to pharmacovigilance visit our safety reports website for more details and feel free to contact us, we will be pleased to help you.
Safety reports. addendum to the clinical overview. acoAzierta
Critical discussion addressing the current benefit/risk balance for the product on the basis of a consolidated version of safety/efficacy data accumulated since the initial MA or the last renewal, taking into account PSURs submitted, suspected adverse reactions reports, additional pharmacovigilance activities and the effectiveness of risk minimization measures contained in the RMP, if applicable.
Then it is explained how to prepare an ACO according to European guidelines and following the required structure.
All about Clinical Trials_Katalyst HLSKatalyst HLS
Introduction to All about Clinical Trials of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Introduction to Expectedness/Unexpectedness Assessment in Drug Safety & Pharmacovigilance of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Clinical Evaluation in the EU for Medical Devices: Understanding the Changes ...Greenlight Guru
A new revision of MEDDEV 2.7.1 is now available and this revision represents a complete rewrite, with massive changes.
The new MEDDEV is both more instructive, and more prescriptive in particular regarding the use of evidence from equivalent devices.
So what exactly are the implications of all these changes for device manufactures?
How does this affect your CERs?
How long is the transition period going to be? (Hint: there’s typically no transition provided for the MEDDEVs).
Join us for this free, 60 minute webinar, presented by our guest Keith Morel, VP of Regulatory Compliance at Qserve Group US Inc., on July 21st.
(You can view the full webinar at: http://www.greenlight.guru/webinar/clinical-evaluation-eu-meddev-2_7_1-rev-4)
Specifically, you will learn:
What is MEDDEV 2.7.1. Rev 4 for Clinical Evaluation in EU and why exact does this matter to device makers?
What are some of the most significant changes? (There are a lot of them)
How does it align with the changes to the new EU MDR?
In what ways will demonstrating “equivalence” now be harder?
How often you must update your CERs now and what qualifications the evaluators must have?
How should you prepare for the increased notified body scrutiny?
How do you perform a clinical literature review to meet the new expectations?
Do you need to write a CER for CE Marking? If not, when else do you need to do this and with what focus?
Software as a Medical Device (SaMD) - IMDRF Definition and Categorisationpi
Following the growing importance of technology in healthcare, Medical Devices have begun to play an increasingly important role in the further development of the life sciences landscape.
One of its more remarkable and fastest growing segments goes under the name Software as a Medical Device. This presentation zooms in on the definition and categorisation, as used by the International Medical Device Regulators Forum.
The aim of Safety reports is describe the safety during the lifecycle of the medicinal product. These reports are necessary during development as well as during the authorization process or renewal. In addition, several of these reports may be required by Health Authorities in case of safety concerns.
This presentation contains a full overview about periodic safety update reports and all the information related with it.
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...László Árvai
The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Bluefish Pharmaceuticals.
Medical Devices Postmarket Surveillance in Europe updatedAnnet Visscher
Medical Device Postmarket Surveillance and Clinical Follow-up under the proposed European Medical Device Regulation updated according to the latest amendments.
Development safety update report (dsur) pharmacovigilance and safetyAzierta
According to ICH guideline E2F (Step 5) on Development Safety Update Reports (DSURs) already implemented since 2011, companies must submit DSURs on a yearly basis for medicinal products involved in clinical trials. The focus of the DSUR is on data and findings from clinical trials of drugs and biologicals, whether they are authorized or not.
DSURs are internationally-harmonized, safety documents covering the safety summary of medicinal products during their development or clinical trial phase.
They are based heavily on the PSUR format already used for updating the safety record of drugs in their marketing phase.
A DSUR should be prepared after the first authorization of a clinical trial worldwide. A copy of the DSUR should be submitted to each concerned European Member State (MS) if a clinical trial is authorized in this MS for this investigational drug (still using the DIBD). Therefore, the first DSUR can be submitted to a concerned MS earlier than 1 year, but the covered reporting period should not be longer than 1 year.
The DSUR presents an annual review & evaluation of safety information:
• Information reported during the current review period and analysis based on previous knowledge of the products’ safety
• Description of new issues that may impact the overall program or specific clinical trials.
• Summarization of current understanding and management of known and potential safety risks to exposed patients.
• Provide an update on the status of the clinical development program.
In Azierta, scientific and healthcare consulting, we are experts in Pharmacovigilance and we have a team of highly qualified drug safety experts who support our clients to manage pharmacovigilance in an optimal way. Our work covers all areas of pharmacovigilance, both at the level of medicines, as well as medical devices and cosmetic products.
If you are interested in the contents of the good practices of pharmacovigilance (GVPs), as well as in other products related to pharmacovigilance visit our safety reports website for more details and feel free to contact us, we will be pleased to help you.
Safety reports. addendum to the clinical overview. acoAzierta
Critical discussion addressing the current benefit/risk balance for the product on the basis of a consolidated version of safety/efficacy data accumulated since the initial MA or the last renewal, taking into account PSURs submitted, suspected adverse reactions reports, additional pharmacovigilance activities and the effectiveness of risk minimization measures contained in the RMP, if applicable.
Then it is explained how to prepare an ACO according to European guidelines and following the required structure.
All about Clinical Trials_Katalyst HLSKatalyst HLS
Introduction to All about Clinical Trials of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Introduction to Expectedness/Unexpectedness Assessment in Drug Safety & Pharmacovigilance of Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Clinical Evaluation in the EU for Medical Devices: Understanding the Changes ...Greenlight Guru
A new revision of MEDDEV 2.7.1 is now available and this revision represents a complete rewrite, with massive changes.
The new MEDDEV is both more instructive, and more prescriptive in particular regarding the use of evidence from equivalent devices.
So what exactly are the implications of all these changes for device manufactures?
How does this affect your CERs?
How long is the transition period going to be? (Hint: there’s typically no transition provided for the MEDDEVs).
Join us for this free, 60 minute webinar, presented by our guest Keith Morel, VP of Regulatory Compliance at Qserve Group US Inc., on July 21st.
(You can view the full webinar at: http://www.greenlight.guru/webinar/clinical-evaluation-eu-meddev-2_7_1-rev-4)
Specifically, you will learn:
What is MEDDEV 2.7.1. Rev 4 for Clinical Evaluation in EU and why exact does this matter to device makers?
What are some of the most significant changes? (There are a lot of them)
How does it align with the changes to the new EU MDR?
In what ways will demonstrating “equivalence” now be harder?
How often you must update your CERs now and what qualifications the evaluators must have?
How should you prepare for the increased notified body scrutiny?
How do you perform a clinical literature review to meet the new expectations?
Do you need to write a CER for CE Marking? If not, when else do you need to do this and with what focus?
Software as a Medical Device (SaMD) - IMDRF Definition and Categorisationpi
Following the growing importance of technology in healthcare, Medical Devices have begun to play an increasingly important role in the further development of the life sciences landscape.
One of its more remarkable and fastest growing segments goes under the name Software as a Medical Device. This presentation zooms in on the definition and categorisation, as used by the International Medical Device Regulators Forum.
The aim of Safety reports is describe the safety during the lifecycle of the medicinal product. These reports are necessary during development as well as during the authorization process or renewal. In addition, several of these reports may be required by Health Authorities in case of safety concerns.
This presentation contains a full overview about periodic safety update reports and all the information related with it.
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...László Árvai
The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Bluefish Pharmaceuticals.
Medical Devices Postmarket Surveillance in Europe updatedAnnet Visscher
Medical Device Postmarket Surveillance and Clinical Follow-up under the proposed European Medical Device Regulation updated according to the latest amendments.
Webinar: Europe's new Medical Device Regulations (MDR)EMERGO
WATCH the recorded webinar here: http://www.emergogroup.com/resources/video-webinar-europe-mdr-changes
The first major revision to device regulations since 2007 has been released and the changes are significant. Although the MDR won't take effect until early 2020, smart companies are planning ahead to beat the crush of companies that will inevitably wait until the last minute, overwhelming EU Notified Bodies. Ronald Boumans, Senior Global Regulatory Consultant for EMERGO (and former IGZ compliance inspector in The Netherlands) outlines the most important changes you need to know in this 35 minute recorded webinar from September 2016. Topics addressed include:
How the MDR is organized
Scope of the legislation
Device classification rules
New clinical evaluation requirements
UDI and EUDAMED database
Adverse event reporting
And much more...
No substantial changes compared to 2004/108/EC (for manufacturers)
Conformity Assessment Procedure: two options
Module A “Internal production control”
Module B “EU type examination” + Module C “Conformity of type based on internal production control”
To improve the internal market for goods and strengthen the conditions for placing a wide range of products on the EU Market, the New Legislative Framework was adopted in 2008
improves market surveillance rules to better protect both consumers and professionals from unsafe products, including those imported from outside the EU:
- sets clear and transparent rules for the accreditation of conformity assessment bodies;
- boosts the quality of and confidence in the conformity assessment of products through stronger and clearer rules on the requirements for the notification of conformity assessment bodies;
- clarifies the meaning of CE marking and enhances its credibility;
- establishes a common legal framework for industrial products in the form of a toolbox of measures for use in future legislation.
Presentation about transparency under the new MDR and IVDR at Informa Medtech Summit in Clinical evaluations and investigations for medical devices track
BSI British Standards' presentation of EU Medical Devices Directive M5 Amendment 93 42 EEC regulatory updates.
Presented at the HKTDC Hong Kong International Medical Devices and Supplies Fair 2009.
By Jan van Lochem, Gert Bos and Suzanne Halliday.
Seminar “Regulatory update on medical devices in Asia and EU”.
It covers the revision of the EU medical device directive, implementation of the revised directive, the key changes, changes to clinical requirements, introduction of technical file sampling, and the impact revision on technical or design dossiers.
How to Make Postmarket Surveillance More Cost EffectiveApril Bright
When it comes to postmarket surveillance (PMS), it’s common for the costs to outweigh the value. But, by working with the right team, you’ll be able to execute a study that maximizes return on investment and minimizes the financial impact of conducting further observational research. Postmarket study challenges that must be addressed include enrollment delays, patient attrition, long-term follow-up, resourcing demands and global payor requirements. This session will provide a case study of one orthopaedic company’s seamless transition between postmarket approval and post-approval studies.
POST-MARKET CLINICAL FOLLOW UP STUDIES FOR MEDICAL DEVICESSharvilModi
PMCF, or Post-Market Clinical Follow-up, is a process mandated for medical devices in the European Union. It involves collecting clinical data and feedback from real-world use after a device is launched. The objective is to assess its performance, safety, and clinical benefits. PMCF helps monitor device safety, identify any new risks or concerns, and evaluate its effectiveness. Manufacturers design a study plan, collect relevant data, analyze it, and document the findings to ensure compliance with regulations. PMCF plays a vital role in ongoing device surveillance and improving patient safety.
Clinical evaluation report cer in a more stringent regulatory- Pepgra HealthcarePEPGRA Healthcare
European regulatory framework has established rules that govern the development, manufacturing, and marketing of medical devices in the European market. Both European and non-European medical device manufacturer’s fall under the purview of the regulatory framework, which is established to
provide condence to the clinicians and the patients that the medical devices and the implantable devices used in the region have been validated for their potential benets and certied as safe for usage.
A compliant CER should support strong clinical evidence that your device achieves its intended purpose without exposing users and patients to risk. The CER must be based on clinical data, which may include clinical data from existing literature, clinical experience, clinical trials, or any combination of the three.
You are required to prepare and submit a clinical evaluation report with your technical file as part of the CE Marking/conformity assessment process. However, approach the CER as a standalone document.
Clinical Evaluation Report for Medical DevicesI 3 Consulting
As per MEDDEV 2.7/1 Rev.4, Clinical Evaluation is a specialized robust method to collect, appraise and analyze clinical data related to a medical device and to interpret if there is satisfactory clinical information (evidence) to establish conformity with pertinent essential requirements for safety and performance when employing the medical device as per the manufacturer's instructions for use.
What you need to know about the Pharmacovigilance guidelines for companies marketing drugs in India. A concise overview of the six modules in the Guidance Document and the responsibilities of the Marketing Authorization Holders.
Pharmacovigilance planning refers to the systematic and proactive approach taken by pharmaceutical companies, regulatory agencies, and other stakeholders to establish strategies and procedures for monitoring the safety of drugs throughout their lifecycle. It involves creating a comprehensive framework to detect, assess, understand, and prevent adverse effects or any other drug-related problems. Here are some key aspects to consider in pharmacovigilance planning
Carlos Langezaal - Eisai Inc, Speaker at the marcus evans Discovery Summit Fall 2011, delivers his presentation on The Importance of Developing a Global Regulatory Strategy towards the Goal of Registration
Design for reimbursement in medical device developmentAmber Hol Horeman
In medical device development it is essential to start with reimbursement strategy from day one to enhance the chance to successful implementation in the healthcare system. This presentation shows the outcomes of a 5 month graduation project to the role of reimbursement in medical device development. The design for reimbursement framework proposed provides an overview for starting entrepreneurs in the complex field of medical devices.
Business Valuation Principles for EntrepreneursBen Wann
This insightful presentation is designed to equip entrepreneurs with the essential knowledge and tools needed to accurately value their businesses. Understanding business valuation is crucial for making informed decisions, whether you're seeking investment, planning to sell, or simply want to gauge your company's worth.
What is the TDS Return Filing Due Date for FY 2024-25.pdfseoforlegalpillers
It is crucial for the taxpayers to understand about the TDS Return Filing Due Date, so that they can fulfill your TDS obligations efficiently. Taxpayers can avoid penalties by sticking to the deadlines and by accurate filing of TDS. Timely filing of TDS will make sure about the availability of tax credits. You can also seek the professional guidance of experts like Legal Pillers for timely filing of the TDS Return.
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
As a business owner in Delaware, staying on top of your tax obligations is paramount, especially with the annual deadline for Delaware Franchise Tax looming on March 1. One such obligation is the annual Delaware Franchise Tax, which serves as a crucial requirement for maintaining your company’s legal standing within the state. While the prospect of handling tax matters may seem daunting, rest assured that the process can be straightforward with the right guidance. In this comprehensive guide, we’ll walk you through the steps of filing your Delaware Franchise Tax and provide insights to help you navigate the process effectively.
Enterprise Excellence is Inclusive Excellence.pdfKaiNexus
Enterprise excellence and inclusive excellence are closely linked, and real-world challenges have shown that both are essential to the success of any organization. To achieve enterprise excellence, organizations must focus on improving their operations and processes while creating an inclusive environment that engages everyone. In this interactive session, the facilitator will highlight commonly established business practices and how they limit our ability to engage everyone every day. More importantly, though, participants will likely gain increased awareness of what we can do differently to maximize enterprise excellence through deliberate inclusion.
What is Enterprise Excellence?
Enterprise Excellence is a holistic approach that's aimed at achieving world-class performance across all aspects of the organization.
What might I learn?
A way to engage all in creating Inclusive Excellence. Lessons from the US military and their parallels to the story of Harry Potter. How belt systems and CI teams can destroy inclusive practices. How leadership language invites people to the party. There are three things leaders can do to engage everyone every day: maximizing psychological safety to create environments where folks learn, contribute, and challenge the status quo.
Who might benefit? Anyone and everyone leading folks from the shop floor to top floor.
Dr. William Harvey is a seasoned Operations Leader with extensive experience in chemical processing, manufacturing, and operations management. At Michelman, he currently oversees multiple sites, leading teams in strategic planning and coaching/practicing continuous improvement. William is set to start his eighth year of teaching at the University of Cincinnati where he teaches marketing, finance, and management. William holds various certifications in change management, quality, leadership, operational excellence, team building, and DiSC, among others.
Attending a job Interview for B1 and B2 Englsih learnersErika906060
It is a sample of an interview for a business english class for pre-intermediate and intermediate english students with emphasis on the speking ability.
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...BBPMedia1
Marvin neemt je in deze presentatie mee in de voordelen van non-endemic advertising op retail media netwerken. Hij brengt ook de uitdagingen in beeld die de markt op dit moment heeft op het gebied van retail media voor niet-leveranciers.
Retail media wordt gezien als het nieuwe advertising-medium en ook mediabureaus richten massaal retail media-afdelingen op. Merken die niet in de betreffende winkel liggen staan ook nog niet in de rij om op de retail media netwerken te adverteren. Marvin belicht de uitdagingen die er zijn om echt aansluiting te vinden op die markt van non-endemic advertising.
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...BBPMedia1
Grote partijen zijn al een tijdje onderweg met retail media. Ondertussen worden in dit domein ook de kansen zichtbaar voor andere spelers in de markt. Maar met die kansen ontstaan ook vragen: Zelf retail media worden of erop adverteren? In welke fase van de funnel past het en hoe integreer je het in een mediaplan? Wat is nu precies het verschil met marketplaces en Programmatic ads? In dit half uur beslechten we de dilemma's en krijg je antwoorden op wanneer het voor jou tijd is om de volgende stap te zetten.
Discover the innovative and creative projects that highlight my journey throu...dylandmeas
Discover the innovative and creative projects that highlight my journey through Full Sail University. Below, you’ll find a collection of my work showcasing my skills and expertise in digital marketing, event planning, and media production.
Improving profitability for small businessBen Wann
In this comprehensive presentation, we will explore strategies and practical tips for enhancing profitability in small businesses. Tailored to meet the unique challenges faced by small enterprises, this session covers various aspects that directly impact the bottom line. Attendees will learn how to optimize operational efficiency, manage expenses, and increase revenue through innovative marketing and customer engagement techniques.
Taurus Zodiac Sign_ Personality Traits and Sign Dates.pptxmy Pandit
Explore the world of the Taurus zodiac sign. Learn about their stability, determination, and appreciation for beauty. Discover how Taureans' grounded nature and hardworking mindset define their unique personality.
Memorandum Of Association Constitution of Company.pptseri bangash
www.seribangash.com
A Memorandum of Association (MOA) is a legal document that outlines the fundamental principles and objectives upon which a company operates. It serves as the company's charter or constitution and defines the scope of its activities. Here's a detailed note on the MOA:
Contents of Memorandum of Association:
Name Clause: This clause states the name of the company, which should end with words like "Limited" or "Ltd." for a public limited company and "Private Limited" or "Pvt. Ltd." for a private limited company.
https://seribangash.com/article-of-association-is-legal-doc-of-company/
Registered Office Clause: It specifies the location where the company's registered office is situated. This office is where all official communications and notices are sent.
Objective Clause: This clause delineates the main objectives for which the company is formed. It's important to define these objectives clearly, as the company cannot undertake activities beyond those mentioned in this clause.
www.seribangash.com
Liability Clause: It outlines the extent of liability of the company's members. In the case of companies limited by shares, the liability of members is limited to the amount unpaid on their shares. For companies limited by guarantee, members' liability is limited to the amount they undertake to contribute if the company is wound up.
https://seribangash.com/promotors-is-person-conceived-formation-company/
Capital Clause: This clause specifies the authorized capital of the company, i.e., the maximum amount of share capital the company is authorized to issue. It also mentions the division of this capital into shares and their respective nominal value.
Association Clause: It simply states that the subscribers wish to form a company and agree to become members of it, in accordance with the terms of the MOA.
Importance of Memorandum of Association:
Legal Requirement: The MOA is a legal requirement for the formation of a company. It must be filed with the Registrar of Companies during the incorporation process.
Constitutional Document: It serves as the company's constitutional document, defining its scope, powers, and limitations.
Protection of Members: It protects the interests of the company's members by clearly defining the objectives and limiting their liability.
External Communication: It provides clarity to external parties, such as investors, creditors, and regulatory authorities, regarding the company's objectives and powers.
https://seribangash.com/difference-public-and-private-company-law/
Binding Authority: The company and its members are bound by the provisions of the MOA. Any action taken beyond its scope may be considered ultra vires (beyond the powers) of the company and therefore void.
Amendment of MOA:
While the MOA lays down the company's fundamental principles, it is not entirely immutable. It can be amended, but only under specific circumstances and in compliance with legal procedures. Amendments typically require shareholder
Post Market Clinical Surveillance, Experience of the Industry by S. Menzl - Abbott Medical Optics (Qserve Conference 2013)
1. Post Market
Clinical Surveillance
View from Industry
2nd Qserve Conference
18-19 November, 2013
Stefan Menzl, PhD
Director, International Regulatory Affairs,
Abbott Medical Optics
2. Content of the Presentation 1/2
• What is Post Market …
– Surveillance?
– Clinical Follow-Up / Surveillance?
• Requirements for Post Market (Clinical) Surveillance
– Current Medical Device Directive
– New Medical Device Regulation
– MEDDEV 2.12-2
– QM-System (ISO13485)
Stefan Menzl 2013
2
3. Content of the Presentation 2/2
• Elements of Post Market (Clinical) Surveillance
– PM(C)F Plan
– Vigilance (incl. Trending)
– Literature Review
– Registries
– Studies
• Challenges for Industry to meet Requirements
– Non harmonized requirements worldwide
– The ‚human factor‘
– Language
–…
Stefan Menzl 2013
3
4. Post Market (Clinical) Surveillance / Follow-Up
Post-market follow-up, ... is a continuous
process …and
shall be part of the manufacturer's postmarket surveillance plan
To this end, the manufacturer shall proactively
collect and evaluate clinical data from the use in
or on humans of a device which is authorized to
bear the CE marking, within its intended purpose
... with the aim of confirming the safety and
performance throughout the expected
lifetime of the device, the continued
acceptability of identified risks and to detect
emerging risks on the basis of factual evidence
Stefan Menzl 2013
4
PMCF
definition
Emphasis
on the
proactive
nature of
the program
PMCF plan
mandatory
unless duly
justified
5. MDD
Requirements for Post Market (Clinical) Follow Up
MDD, new Annex X, 1.1c
Requirement to actively update clinical assessment with data from
‘Post Market Surveillance’
ACTION
Required update of risk assessment
and
clinical assessment in defined frequency
Consider PMS data
(incl. Events and Literature)
Requirement to have PMS-Plan for every
Product-family
Stefan Menzl 2013
5
6. MDD
Post Market (Clinical) Surveillance / Follow-Up
MDD (93/42/EEC) requires PMS and PMCF
Additional requirement to comply with ‚state of the art‘
Literature-screening as part of PMS, clinical assessment and PMCF
Clinical assessment required for all classes of devices (2007/47/EEC)
ER (6a)
• Safety & Effectiveness
• Beneficial risk/benefit ratio
Stefan Menzl 2013
6
7. New Medical Device Regulation
Proposal Post Market Clinical Follow-Up
″ ... PMCF shall be performed pursuant to a
documented method laid down in a PMCF plan ...
″ specify general methods and procedures, such as
gathering of clinical experience gained, feedback from
users, screening of scientific literature and of other
sources of clinical data ...
″ The notified body shall periodically, at least once
every 12 months, carry out appropriate audits and
assessments to make sure that the manufacturer
applies the approved quality management system
and the post-market surveillance plan.”
Stefan Menzl 2013
7
8. MEDDEV 2.12-2
Post Market (Clinical) Surveillance / Follow-Up
MEDDEV 2.12-2
Definitions
PMCF study: a study carried out following the CE marking of a
device and intended to answer specific questions relating to
clinical safety or performance (residual risk) of a device when
used in accordance with its approved labeling
PMCF plan: the documented, proactive, organized methods
used to collect clinical data from actual use in humans on a
specific CE marked device (or device group) with the aim of
confirming long term clinical performance and safety, the
acceptability of identified risks, and to detect emerging risks on
the basis of factual evidence
Stefan Menzl 2013
8
9. QMS ISO13485
Post Market (Clinical) Surveillance / Follow-Up
Requirements of Quality-management System (Annex II.3)
• Known risks (e.g. from literature or event reporting)
need to be addressed in Risk-Management-Process and
have to be considered in clinical assesssment
• Remaining risks need to be addressed in labeling
• Medical benefit needs to outweigh remaining risk
(risk-benefit ratio)
Stefan Menzl 2013
9
10. Elements of Post Market (Clinical) Surveillance / Follow-Up
Post Market Surveillance Plan
Featured prominently
in the proposal of MD
regulations released
on Sept 26
Importance of
Post Market Clinical Follow Up
Importance to apply the
concept throughout the life-cycle
of the device
Stefan Menzl 2013
10
11. Elements of Post Market (Clinical) Surveillance / Follow-Up
Post Market Surveillance Plan
• PMCF should be conducted for any device that has used clinical
data from equivalence devices alone as the basis for the clinical
evaluation.
• The plan should ensure that residual risks identified for the
equivalent devices are addressed
Stefan Menzl 2013
11
12. Elements of Post Market (Clinical) Surveillance / Follow-Up
Post Market Surveillance Plan
The data shall be reviewed at regular intervals
The plan shall define:
– Frequency of review to ensure continuous monitoring of benefit/risk
ratio (including patient quality of life and public health impact)
– By whom
– Trending methodology: identification of trend and need for
preventive/corrective action
Stefan Menzl 2013
12
13. Elements of Post Market (Clinical) Surveillance / Follow-Up
Post Market Surveillance Plan- Content
The plan shall define the source of data and the means to
collect those data and shall be proportional to the risk of
device/device family
The plan may include:
– Complaints Handling
– Return Product Analysis
– Vigilance Reports
– Literature Review
– Registry Review
– PMCF
– Regulatory Feedback
Stefan Menzl 2013
13
14. Elements of Post Market (Clinical) Surveillance / Follow-Up
PMCF – Vigilance (New Medical Device Regulation)
″ ... European system for the notification and
evaluation of incidents and field safety corrective
actions ...
Advantage
Existing company system
Low additional cost
Challenges
Reactive
Issues late in the game
Stefan Menzl 2013
14
15. Elements of Post Market (Clinical) Surveillance / Follow-Up
PMCF – Literature Review (New Medical Device Regulation)
″ The process of reading, analyzing, evaluating, and
summarizing scholarly materials about a specific topic.”
Options
Review relevant sources at regular intervals, e.g. PubMed
Conferences
Journal alerting Services
Advantage
Relatively cheap
Access to data world wide
Challenges
Reactive
Data typically limited and heterogeneous
Stefan Menzl 2013
15
16. Elements of Post Market (Clinical) Surveillance / Follow-Up
PMCF – Registries (New Medical Device Regulation)
Options – several
Paper/ EDC forms
Single/ multi center
...
Advantages
Value for money
Low site threshold
...
Challenges
No efficacy/ added value data
Stefan Menzl 2013
16
17. Elements of Post Market (Clinical) Surveillance / Follow-Up
PMCF – Studies (New Medical Device Regulation)
Options
Small scale single arm
RCT
Advantages
Efficacy and/ or added value
RCT is gold standard
Challenges
Not daily practice
Huge investment
Blinding
Stefan Menzl 2013
17
18. Elements of Post Market (Clinical) Surveillance / Follow-Up
PMCF – Studies
When to do a PMCF study
• Presence of residual risk that may impact the benefit/risk ratio
• To examine long term performance and/or safety
• To examine the performance and/or safety of the device in a more
representative population of users and patients
• PMCF study is expected, a justification needs to be given when not
performed, e.g. medium/long term safety is already known from
previous use, other appropriate PMS activities provide sufficient data
to address the risks
Stefan Menzl 2013
18
19. Elements of Post Market (Clinical) Surveillance / Follow-Up
PMCF – Studies
Elements of a PMCF study
• PMCF plan:
– Research questions, objectives and related endpoints
– Scientifically sound design with appropriate rationale and statistical
analysis plan
• Implementation of the study according to plan
• Analysis of the data
• Appropriate conclusions
Stefan Menzl 2013
19
20. Elements of Post Market (Clinical) Surveillance / Follow-Up
PMCF – Studies
Outcome
• Conclusions to be part of the clinical evidence report
• Depending on the conclusions, an update of the Essential
Requirements checklist and risk assessment may be appropriate
• Changes could result in corrective/preventive actions like
– Labeling changes
– Changes to manufacturing process
– Design changes
– Public health notifications
Stefan Menzl 2013
20
21. Post Market Clincal Follow Up
Role of the Notified Body
• The Notified Body will review the PMCF procedures and plans as
part of design review (class III) or tech file review and
– Verify compliance of the plans to Annex X, meddev guidance and
standards
– Evaluate the need for a PMCF plan
– Assess the appropriateness of the PMCF plan
– Assess the justification given for not conducting a specific PMCF
plan
– Verify that data from PMCF plans is used to update the clinical
evaluation
Stefan Menzl 2013
21
22. Practically meeting post-market requirements
The Challenge of non-harmonized Requirements
The challenge to meet international Vigilance requirements
• Country specific requirements
• Other challenges
Possible solutions to meet the challenge
• Harmonization
• Company internal processes and systems
Stefan Menzl 2013
22
24. Practically meeting post-market requirements
Other Challenges (than diverse regulation)
• The available information is different from country to country and from
customer to customer
• The language barrier
• Cultural approach to the reporting of complaints
• Availability of technical expertise in every country
• Different classification of products (drug / device) depending on country
regulation
• Responsibility for reporting are different from country to country
(subsidiary or distributor)
Stefan Menzl 2013
24
25. Ensuring safety data is consistently up-to-date
Elements in addition to complaint handling and vigilance
• Literature reviews
• Post market clinical follow up, Post market clinical studies
• Customer surveys
• Feedback from technical service
•…
Stefan Menzl 2013
25
26. Ensuring safety data is consistently up-to-date
Literature reviews
• Proactive measure for PMS
• Which journals
• Abstracts
• Presentations at conventions
• ‚yellow press‘ (e.g. BSE crisis)
• Define the process !!!
• Responsibility & Frequency
Stefan Menzl 2013
26
28. New Medical Device Regulation
PMCF - Conclusion
PMS under new Medical Device Regulation
More stringent and controlled
Various Options
Literature Review
Registries
Randomised Controlled Studies
…..
Stefan Menzl 2013
28
29. New Medical Device Regulation
Post Market Surveillance – Potential Consequences
PMS plan itself
Product Improvements
Extend, maintain or reduce PMCF/registry
Product Labeling / IFUs
Extend, maintain or reduce Product Training / User Training
Update of Risk Management
FSCAs
Stefan Menzl 2013
29
30. AMO Products covered by the PMS/PMCF program
Vision. For Life.
AMO’s strategy is to deliver advanced life-improving vision technologies for people of all ages
31. Three Integrated Businesses Provide
Vision. For Life.
Eye Care Professionals
Corneal
Refractive
Cataract
Proprietary formulations designed
to protect and lubricate ocular
surfaces
Advanced laser technologies
designed to deliver freedom from
eyeglasses
Leading products for intraocular
procedures that optimize visual
function
32. Abbott Medical Optics
3,700+ employees worldwide
• Direct sales in 29 countries & presence in more than 60 countries
Russia
Sweden
Canada
Ireland
Netherlands
Spain
United States
Japan
China
Mexico
India
Puerto Rico
Africa
Singapore
South
America
3 Mfg/R&D sites
3 Mfg sites
1 Global R&D site
4 Regional hubs
Australia
33. Cataract -- IOL Platforms
• Tecnis® IOL
– Monofocal, aspheric IOL designed to correct spherical
aberration to zero
• Tecnis® Toric IOL
– Toric IOL designed to correct preexisting corneal astigmatism
• Tecnis® Multifocal IOL
– Diffractive, aspheric IOL that provides near, intermediate and
distance vision with exceptionally high spectacle
independence
– Enjoys premium pricing and patient-shared billing in the U.S.;
co-pay in several markets outside U.S.
• Synchrony® Accommodating IOL
– Addresses presbyopia in cataract patients
– Dual optic accommodating IOL designed to allow patients to
see near, intermediate and distance vision
– Approved in Europe; pending FDA approval in U.S.
34. Cataract -- Phaco and Visco Platforms
• Healon® Viscoelastics
– Family of viscoleastics that provides a range
of viscosity to satisfy different surgical needs
• WhiteStar Signature™
Phacoemulsification System
• Ultrasonic device that emulsifies and extracts
a cataractous lens using less heat and
turbulence and FusionTM Fluidics to optimize
outcomes
• Ellips™ handpiece provides longitudinal
combined with transversal motion
35. Refractive Technology Suite
• iFSTM Laser
– Femtosecond laser that focuses pulses of light
below the surface of the cornea to create the flap
before a LASIK procedure is performed
• WaveScan WaveFront System
– Diagnostic device that captures unique
imperfections in each patient’s eyes and creates a
personalized treatment plan
– iDesignTM system is next generation technology
• Star S4 IR Laser System
– Computer-driven excimer laser that corrects
refractive errors by reshaping the cornea
– Performs Advanced CustomVue procedure,
which corrects unique imperfections in each
patient’s eyes and is capable of treating the
industry’s broadest range of refractive conditions
36. Corneal Products
• RevitaLens Ocutec Multipurpose Disinfecting
Solution
– Next-generation multipurpose disinfecting
solution for silicone hydrogel and conventional
soft contact lenses
• Complete Multipurpose Solution
– Convenient, single-bottle solution formulated to
effectively clean and disinfect contact lenses
• Oxysept Ultracare System
– Hydrogen peroxide system that provides
powerful disinfection efficacy for contact lenses
• Blink Tears
– Family of lubricating eye drops designed to
provide relief to dry eye patients
37. Post Market Clinical Follow-UP
“Everything should
be made as simple
as possible, but not
simpler”
Stefan Menzl 2013
37